Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 6/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 5/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 4/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | PRKCH | P24723 | 4/20 | 1.00 |
| ▸ | PRKCI | P41743 | 4/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 4/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 4/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 4/20 | 1.00 |
| ▸ | MYLK | Q15746 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| K-252A SCHEMBL13993461 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL31181849 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL29355962 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13485248 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL15575821 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL24112155 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL13787898 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL968886 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL32665760 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 | |
| K-252A SCHEMBL29660621 | 1.00 | NTRK1 (1.00) | NTRK1PRKCQKDRMAP3K11MAP3K9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | LOXO ONCOLOGY, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4041259-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | University of Houston System (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-3980563-A2 | NTRK FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202788-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | NTRK1 22/4885PRKCQ 569/4885KDR 517/4885 |
| US-12138250-B2 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile | RET, ALK, BRAF | NTRK1 22/4885PRKCQ 569/4885KDR 517/4885 |
| US-11998545-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NTRK1 344/4885PRKCQ 560/4885KDR 787/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | NTRK1 310/4885PRKCQ 1543/4885KDR 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.